CD274 and neoplasm: When evaluating other biomarkers of response to ICI, such as PD-L1 expression, TMB, and tumor-associated immune cells (e.g., TILs density), combining the assessment of the NLR may allow to further stratify patients with different likelihoods of deriving a significant clinical benefit while not increasing costs nor adding complexity to the evaluation.